Search hospitals > Kansas > Manhattan
Cancer Center of Kansas-Manhattan
Claim this profileManhattan, Kansas 66502
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Non-Small Cell Lung Cancer
108 reported clinical trials
2 medical researchers
Summary
Cancer Center of Kansas-Manhattan is a medical facility located in Manhattan, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Cancer Center of Kansas-Manhattan is involved with conducting 108 clinical trials across 303 conditions. There are 2 research doctors associated with this hospital, such as Shaker Dakhil, M.D. and Dennis F. Moore.Area of expertise
1Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Shaker Dakhil, M.D.Cancer Center of Kansas - Wichita5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
81 reported clinical trials
168 drugs studied
Dennis F. MooreAscension Via Christi Hospitals Wichita3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
27 reported clinical trials
74 drugs studied
Clinical Trials running at Cancer Center of Kansas-Manhattan
Breast Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Lung Cancer
Bladder Cancer
Renal Cell Carcinoma
Cancer
Multiple Myeloma
Squamous Cell Carcinoma
Meningioma
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cancer Center of Kansas-Manhattan?
Cancer Center of Kansas-Manhattan is a medical facility located in Manhattan, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Cancer Center of Kansas-Manhattan is involved with conducting 108 clinical trials across 303 conditions. There are 2 research doctors associated with this hospital, such as Shaker Dakhil, M.D. and Dennis F. Moore.